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ANALISIS GEN P27 DAN CYCLIN D1 DALAM GLIOMA DAN MENINGIOMA 
DENGAN MENGGUNAKAN TEKNIK GENETIK MOLEKUL, IMMUNOHISTOKIMIA 
DAN MIKROSKOPI ELEKTRON IMMUNOGOLD 
 
ABSTRAK 
 
 
Meningioma dan glioma merupakan dua jenis tumor otak yang paling kerap di 
laporkan di seluruh dunia. Kedua-dua jenis kanser ini mungkin berlaku akibat daripada 
gangguan pada kitaran sel yang normal yang dikawal rapi oleh gen p27 dan cyclin D1. 
Kajian ini dijalankan untuk menentukan status mutasi gen p27 dan cyclin D1, tahap 
pengeksresan protein dan lokasi kedua-dua protein tersebut melalui beberapa analisis 
termasuklah analisis genetik molekul, immunohistokimia, mikroskopi elektron 
immunogold. Analisis genetik molekul menunjukkan mutasi berlaku pada ekson 4 gen 
cyclin D1 tetapi tiada mutasi dilaporkan pada ekson 5 gen cyclin D1, dan ekson 1 dan 2 
gen p27 yang turut dikaji. Lima mutasi yang berlainan telah dikesan dalam 2 sample 
glioma (8.0%) dan 3 sampel meningioma (11.5%). Penjujukan DNA yang dilakukan 
pada dua sampel glioma tersebut menunjukkan kehadiran mutasi tidak bererti akibat 
perubahan nukleotida C kepada T pada kodon 223 (Lys223Lys). Di dalam sample 
glioma yang pertama, kami juga menjumpai delesi nukleotida G pada kodon 214 yang 
mengakibatkan mutasi anjakan rangka (Pro214Arg). Selain itu, kami juga menjumpai 
mutasi salah erti pada sampel glioma yang kedua. Perubahan nukleotida T kepada C 
telah dijumpai pada kodon 215 dan 217 yang telah menyebabkan perubahan asid 
aspartik kepada Glysin pada dua lokasi yang berlainan. Penskrinan mutasi dalam kes 
meningioma telah menemui 3 mutasi tidak bererti dan 3 mutasi salah erti dalam 3 
sampel yang berasingan. Dalam ketiga-tiga sampel, kami menjumpai 3 kes perubahan 
nukleotida C kepada T yang mengakibatkan mutasi tidak bererti pada kodon 223 
(Lys223Lys). Dalam sampel kedua dan ketiga, kami menjumpai perubahan nukleotida T 
kepada C pada kodon 215 yang mengakibatkan mutasi salah erti (Asp215Gly). Satu lagi 
 xx
mutasi salah erti telah dijumpai pada kodon 217 yang menyebabkan perubahan 
nukleotida T kepada C dalam sampel meningioma yang ketiga. Analisis imunohistokimia 
pada kumpulan sampel yang sama menunjukkan protein p27 mengalami peningkatan 
dalam pengekspresannya dalam semua kes termasuklah meningioma (82.6%), glioma 
gred rendah (80.0%) dan glioma gred tinggi (84.6%). Kami kemudiannya menjumpai 
peningkatan dalam pengekspresan protein cyclin D1 dalam kes meningioma (70.8%) 
dan pengurangan dalam kes glioma peringkat tinggi (76.9% kes adalah mengalami 
pengekspresan protein cyclin D1 yang rendah). Kami juga menjumpai kadar 
pengekspresan yang sama dalam kes glioma peringkat rendah di mana 50% daripada 
kesnya mengalami pengekspresan protein yang rendah dan 50% mengalami 
pengekspresan protein yang tinggi). Analisis mikroskopi elektron immunogold pada 
protein p27 dan cyclin D1 menunjukkan kehadiran kedua-dua protein pada sitoplasma 
dan nukleus sel. Analisis statistik tidak menunjukkan sebarang hubungkait yang 
signifikan antara kehadiran mutasi pada gen cyclin D1 dengan pengurangan dalam 
tahap pengekspresan proteinnya dala kedua-dua kes meningioma (p=0.616) dan glioma 
(p=0.905).  
 
Kata kunci: meningioma; glioma; p27; cyclin D1; genetik molekul; imunohistokimia; 
mikroskopi elektron imunogold  
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ANALYSIS OF P27 AND CYCLIN D1 GENES IN GLIOMAS AND MENINGIOMAS 
USING MOLECULAR GENETIC, IMMUNOHISTOCHEMICAL AND IMMUNOGOLD 
ELECTRON MICROSCOPIC TECHNIQUES  
 
 
ABSTRACT 
 
 
 Meningiomas and gliomas are two most commonly reported brain tumor cases 
worldwide. These types of tumors might occur due to the disruption of the normal cell 
cycle which is highly controlled by p27 and cyclin D1 genes. This study was performed 
to determine the mutational status of p27 and cyclin D1, level of both protein expression 
and the localization of both proteins at ultrastructural level via analyses of molecular 
genetic, immunohistochemistry and immunogold electron microscopy respectively. The 
molecular genetic analysis revealed mutations in exon 4 of cyclin D1 gene but none was 
detected in other studied regions of exon 5 of cyclin D1 gene and exon 1 and 2 of p27 
gene. Five different mutations were detected in 2 glioma (8.0%) and 3 meningioma 
(11.5%) samples. DNA sequencing for the two gliomas samples revealed the presence 
of non-sense mutation which resulted to the change of C to T nucleotide at codon 223 
(Lys223Lys). In the first glioma sample, we also detected a G base deletion at codon 
214 which caused a frameshift mutation (Pro214Arg). In addition to that, we also found 
two other missense mutations in the second glioma sample. T to C nucleotide changes 
were detected at codon 215 and codon 217 which caused aspartic acid to Glycine 
changes in two different loci. Screening of mutations in meningiomas cases revealed 3 
cases of non-sense mutations and 3 cases of missense mutations in a total of 3 
samples. In all 3 samples, we found 3 cases of C to T nucleotide change which resulted 
to non-sense mutations at codon 223 (Lys223Lys). In the second and third meningioma 
samples, we found an additional of T to C nucleotide changes at codon 215 which 
caused missense mutations (Asp215Gly). Another missense mutation was found at 
codon 217 which showed T to C nucleotide change in the third meningioma sample. 
 xxii
Immunohistochemistry analysis of the same group of samples revealed p27 protein 
overexpression in all cases including meningiomas (82.6%), low grades gliomas (80.0%) 
and high grades gliomas (84.6%). We subsequently found high level of cyclin D1 
expression in meningiomas (70.8%), equal expression of cyclin D1 in low grades of 
gliomas (50% are low expressors and 50% are high expressors), and downregulation of 
the protein in higher grades of gliomas (76.9% were low expressors). Immunogold 
electron microscopy analysis of cyclin D1 and p27 proteins showed that both proteins 
were found to be localized at cytoplasm and nucleus of the cells. Our statistical analysis 
gave no significant correlation between the presence of cyclin D1 mutations with the 
downregulation of the protein in both meningiomas (p=0.616) and gliomas (p=0.905).  
 
Keywords: meningiomas; gliomas; p27; cyclin D1; molecular genetics; 
immunohistochemistry; immunogold electron microscopy   
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CHAPTER I 
 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
 
Cancer is a complex and unpredictable genetic disease which is referred to as an 
abnormal growth of cells.  It is a multifaceted disease, which has long been regarded as 
a genetic disease (Cornelisse, 2003b). In 1914, the famous biologist Theodor Boveri 
postulated that abnormal distribution of chromosome could be the cause of cancer. 
Furthermore, he suggested that tumor could arise from a single abnormal cell 
(monoclonal origin), and predicted that specific chromosomal changes and genetic 
instability are important for tumor development (Cornelisse, 2003a). His opinion was 
extensively supported by many researchers, postulating that the original cause of cancer 
is by the accumulation of genetic alterations and consequently gene expression pattern 
changes (Evan and Vousden, 2001, Fingleton and Coussens, 2005, Garnis et al., 2004, 
Zingde, 2001) which could allow them to grow outside their normal growth restraints 
(Garnis et al., 2004). The accumulation of genetic aberrations are thought to drive the 
progression of normal cells through hyperplastic and dysplastic stages to invasive 
cancer and, finally, metastatic disease (Garnis et al., 2004). Cancer cells posses the 
ability to invade and metastasize (Zingde, 2001), as well as to induce vascularization of 
the tumour in order to receive oxygen and nutrients (angiogenesis), and to suppress 
programmed cell death (apoptosis) (Garrett, 2001, Zingde, 2001).   
 
Several essential steps are compulsory for normal cells to become cancer cells. 
Researches on experimental carcinogenesis in animals have shown that cancer 
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progression involves processes of initiation, promotion and progression, which are all 
involving various genetic alterations. Initiation step is an irreversible and not 
recognizable as a pathological entity. Promotion is a step which facilitates the 
expression of the initiated phenotype. Finally, progression is representing step for further 
phenotypic alterations in the initiated cells (Zingde, 2001).  
 
The alterations which may occur during the three important steps of initiation, promotion 
and progression in cancer development may involve oncogenes and tumor suppressor 
genes. These two types of genes have been marked as genes responsible for the 
cancer phenotype (Zingde, 2001) which can deregulate cellular proliferation by loss of 
genes that normally check the cell growth (the tumor suppressor genes) and by the gain 
of functions of oncogenes that either promote cellular proliferation or prevent cell death 
(Perry, 2001). Oncogenes (from Greek onkos, tumor) can be defined as the activated 
forms of normal cellular genes whose protein products are involved in cell signaling 
governing cell survival, proliferation and differentiation (Perry, 2001). At present, over 
100 oncogenes are now known and the listings of these are available at 
www.ncbi.nlm.gov/ncicgap/ (Zingde, 2001). Oncogenes were originally identified as 
sequences in the genome of animal tumor viruses that could transform normal cells into 
tumor cells. Through a huge breakthrough, there was an important discovery showing 
that similar sequences called proto-oncogenes, could be demonstrated in the DNA of 
normal cells. Proto-oncogenes are believed to have the ability to transform into 
becoming true oncogenes by mutations leading to abnormal activation (Cornelisse, 
2003b) or if they are abnormally expressed in the cell (Melkoumian, 2001). Proto-
oncogenes or c-oncogenes (cellular homologues of DNA, c-onc) are genes that have 
been identified as genes coding for components of the mitogenic signaling cascades and 
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growth control (Zingde, 2001) which normally involved in the regulation of cell 
proliferation (Melkoumian, 2001). 
 
Tumor suppressor gene is a gene that reduces the probability that a cell in a multicellular 
organism will turn into a tumor cell. So far, more than 30 tumor suppressor genes have 
been identified (Cornelisse, 2003b, Zingde, 2001), and the majority of the genes are 
highly associated with the familial cancer syndrome. In contrast to oncogenes, which are 
mainly components of growth-signal transduction pathways, tumor suppressor gene 
products have quite diverging functions. Several of the genes’ products control the DNA 
damage-repair signaling, and thus guard the integrity of our genome (Cornelisse, 
2003b). An important criterion of tumor suppressor gene is the demonstration of loss-of-
function or inactivating mutations in both copies of the gene. The reported mechanisms 
by which could abolish the normal functions of the tumor suppressor genes include loss 
of heterozygosity, methylation, cytogenetic aberrations, genetic mutations, gain of 
autoinhibitory function and polymorphism (Zingde, 2001).       
 
The alterations of various oncogenes and tumor suppressor genes which control the 
normal cell cycle progression are suggested to be involved in the progression of many 
tumor types. The alteration may cause disruption of normal functions of the genes and 
lead to the uncontrolled proliferation of cancer cells (Garrett, 2001). However, 
Monceviciu-te-Eringiene (2005) (Eringiene, 2005) has suggested that genes alterations 
are playing the second important role in causing cancers. He proposed that the 
evolutionary resistance and its variability have an immense power to initially drive and 
control the progression of carcinogenesis. This resistance mechanism can be 
designated as physiological or natural, which requires resistance towards chemical, 
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physical and biological factors. The genetic changes on the other hand, will further help 
the cancer cells to survive under extreme condition. 
 
1.1.1 Definition and category of brain tumors 
 
Tumors of the central nervous system (CNS) are usually devastating because they often 
affect children, are difficult to treat, and frequently cause mental impairment or death. 
CNS tumors are reported as the second most common neoplasm in children, after 
leukemia (Levy, 2005).  
 
A tumor is basically referred to as a mass or growth of abnormal cells. Tumors found in 
the brain typically are categorized as primary or secondary tumors. Primary brain tumors 
originate in the brain and can be cancerous (malignant) or non-cancerous (benign). 
Secondary tumors are tumors which spread to the brain from another site such as lung 
and breast cancer, which are the most common cause of brain metastases. Besides 
that, brain metastases are also found originating from unknown primary (10-15%), 
melanoma (10%) and gastrointestinal carcinoma (5%).  This phenomenon usually 
occurs in 10-30% of all cancer patients (Kaye and Jr., 2001b).  
 
Primary benign and primary malignant brain tumors are broadly classified by the tissue 
of origin. CNS tumors represent a diverse group of neoplasms of the brain and spine 
with varying histology (Levy, 2005). The major brain tumor histology groups are: tumors 
of neuroepithelial tissue, tumors of cranial and spinal nerves, tumors of the meninges, 
lymphomas and hematopoietic neoplasms, germ cell tumors and cysts, tumors of the 
sellar region, and local extensions from regional tumors (Doolittle, 2004).  
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Benign brain tumors are usually slower growing, easier to remove and less likely to recur 
than malignant brain tumors. Malignant brain tumors can grow rapidly, crowding or 
destroying nearby brain tissue. However, in a small number of cases even benign brain 
tumors can cause serious problems or be life threatening. Initial evaluation of suspected 
CNS tumor depends on the presenting illness, symptoms, and available resources at the 
health center, which provides the specific management for the patients (Doolittle, 2004).  
 
Brain tumors are classified depending on the origin and seriousness of the tumor. To 
date, brain tumor groups can be referred to the World Health Organization (WHO) brain 
tumor classification. WHO recognizes 126 different types of central nervous system 
tumors of which some common types of primary tumors are astrocytomas, 
medulloblastomas, meningiomas and oligodendrogliomas. 
 
These tumors are extremely diverse, biologically and in their response to treatment. 
Meningiomas are the most common non-malignant brain tumors in adults, and are 
curable with surgery. Glioblastomas, the most common malignant brain tumors in adults, 
are probably the most resistant of all cancers to treatment.  
 
Treatment for central nervous system cancers includes surgery, radiation therapy and 
chemotherapy. These therapies may be delivered alone or in combination. Although 
neurosurgical techniques, radiation and chemotherapy have undergone various 
advances, brain tumors are still retaining their dismal prognosis and the patients are 
usually dying after certain period of time (Lam and Breakefield, 2001).  
 
 
 
 6
1.2 CENTRAL NERVOUS SYSTEM TUMORS 
 
1.2.1 CENTRAL NERVOUS SYSTEM TUMORS CLASSIFICATION ACCORDING TO 
WORLD HEALTH ORGANIZATION (WHO) 
 
The first edition of Central Nervous System (CNS) classification was published in 1979 
which required almost a decade to be completed. The second edition of the tumors 
classification arose in 1993 after the introduction of immunohistochemistry which helped 
a lot in upgrading the system of classification. Improvement of the previous classification 
system has led to a new publication of the system which was done in 2000 and it will be 
used for the next 5 years. The Table 1.1 below shows the latest classification system of 
central nervous system tumors (Kleihues et al., 2002).  
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Table 1.1: Classification of Tumors of the Nervous System.  
Tumors of Neuroepithelial Tissue Dysembroplastic neuroepithelial tumor 9413/0
Astrocytic tumors Gangglioglioma  9505/1
Diffuse astrocytoma 9400/31 Anaplastic gnagglioglioma  9505/3
   Fibrillary astrocytoma 9420/3 Central neurocytoma 9506/1
   Protoplasmic astrocytoma 9410/3 Cerebellar liponeurocytoma 9506/1
   Geminocytic astrocytoma 9411/3 Paraganglioma of the filum terminale 8680/1
Anaplastic astrocytoma 9401/3 Neuroblastic tumors
Glioblastoma  9440/3 Olfactory neuroblastoma 
(Aesthesioneuroblastoma) 
9522/3
   Giant cell glioblastoma 9441/3 Olfactory neuroepitelioma 9523/3
   Gliosarcoma  9442/3 Neuroblastoma of the adrenal gland 
and sympathetic nervous system 
9500/3
Pilocytic astrocytoma 9421/1 Pineal parenchymal tumors 
Pleomorphic xanthoastrocytoma 9424/3 Pineocytoma  9361/1
Subependymal giant cell 
astrocytoma 
9384/1 Pineoblastoma  9362/3
Oligodendroglial tumors Pineal parenchymal tumor of 
intermediate differentiation 
9362/3
Oligodendroglioma  9450/3 Embryonal tumors
Anaplastic oligodendroglioma 9451/3 Medulloepithelioma  9501/3
Mixed gliomas Ependymoblastoma  9392/3
Oligoastrocytoma  9382/3 Medulloblastoma  9470/3
Anaplastic oligoastrocytoma 9382/3    Desmoplastic   
   medulloblastoma 
 
9471/3
Ependymal tumors    Large cell medulloblastoma 9474/3
Ependymoma  9391/3    Medullomyoblastoma  9472/3
   Cellular  9391/3    Melanotic medulloblastoma 9470/3
   Papillary  9393/3 Supratentorial primitive 
neuroectodermal tumor 
 
9473/3
   Clear cell 9391/3    Neuroblastoma  9500/3
   Tanycytic  9391/3    Ganglioneuroblastoma  9490/3
Anaplastic ependymoma 9392/3 Atypical teratoid/rhabdoid  9508/3
Myxopapillary ependymoma 9394/1 Tumors of Peripheral Nerves 
Subependymoma  9383/1 Schwannoma
Choroid plexus tumors (Neurilemmoma, Neurinoma) 9560/0
Choroid plexus papilloma 9390/0    Cellular 9560/0
Choroid plexus carcinoma 9390/3    Plexiform  9560/0
Glial tumors of uncertain origin    Melanotic  9560/0
Astroblastoma  9430/3 Neurofibroma  9540/0
Gliomatosis cerebri 9381/3    Plexiform  9550/0
Chordoid glioma of the 3rd ventricle 9444/1 Perineurioma  9571/0
Neuronal and mixed neuronal-glial tumors    Intraneural perineurioma 9571/0
Gangliocytoma  9492/0    Soft tissue perineurioma 9571/0
Dysplastic gangliocytoma of 
cerebellum (Lhermitte-Duclos) 
9493/0 Malignant peripheral nerve sheath 
tumor (MPNST) 
 
9540/3
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Desmoplastic infantile 
astrocytoma/ganglioglioma 
 
9412/1 
   Epithelioid 9540/3
   MPSNT with divergent  
   mesenchymal and/or  
   epithelial differentiation 
 
 
9540/3 
Osteoma  9180/0
   Melanotic  9540/3 Osteosarcoma  9180/3
   Melanotic psammomatous 9540/3 Osteochondroma  9210/0
Tumors of the Meninges Hemangioma  9120/0
Tumors of meningothelial cells Epithelioid hemangioendothelioma  9133/1
Meningioma 9530/0 Hemangiopericytoma  9150/1
   Meningothelial  9531/0 Angiosarcoma  9120/3
   Fibrous (fibroblastic) 9532/0 Kaposi sarcoma  9140/3
   Transitional (mixed) 9537/0 Primary melanocytic lesions  
   Psammomatous  9533/0 Diffuse melanocytosis  8728/0
   Angiomatous  9534/0 Diffuse melanocytosis  8728/0
   Microcystic  9530/0 Malignant melanoma  8720/3
   Secretory  9530/0 Meningeal melanomatosis 8728/3
   Lymphoplasmacyte-rich 9530/0 Tumors of uncertain histogenesis 
   Metaplastic  9530/0 Hemangioblastoma  9161/1
   Clear cell  9538/1 Lymphomas and Hemopoietic Neoplasms
   Chordoid  9538/1 Malignant lymphomas  9590/3
   Atypical  9539/1 Plasmacytoma  9731/3
   Papillary  9538/3 Granulocytic sarcoma  9930/3
   Rhabdoid  9538/3 Germ Cell Tumors
   Anaplastic meningioma 9530/3 Geminoma  9064/3
Mesenchymal, non-meningothelial tumors Embryonal carcinoma 9070/3
Lipoma  8850/0 Yolk sac tumor  9071/3
Angiolipoma  8861/0 Choriosarcoma  9100/3
Hibernoma  8880/0 Teratoma  9080/1
Liposarcoma (intracranial) 8850/3    Mature  9080/0
Solitary fibrous tumor  8815/0    Immature  9080/3
Fibrosarcoma  8810/3    Teratoma with malignant  
   transformation 
 
9084/3
Malignant fibrous histiocytoma  8830/3 Mixed germ cell tumors 9085/3
Leiomyoma  8890/0 Tumors of the Sellar Region 
Leiomyosarcoma  8890/3 Craniopharyngioma  9350/0
Rhabdomyoma  8900/0    Adamantinomatous   9351/1
Rhabdomyosarcoma  8900/3    Papillary  9352/1
Chondroma  9220/0 Granular cell tumor 9582/0
Chondrosarcoma  9220/3 
  
Morphology code of the International Classification of Diseases for Oncology (ICD-O) 
and the Systematized Nomenclature of Medicine (SNOMED). Behaviour is coded /0 for 
benign tumors, /1 for low or uncertain malignant potential or borderline malignancy, /2 for 
in situ lesions and /3 for malignant tumors. 
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1.2.2 TYPES OF CENTRAL NERVOUS SYSTEM TUMORS 
 
1.2.2.1 GLIOMAS 
 
Gliomas were described as fast growing, poorly circumscribed lesions which diffusely 
infiltrated but did not destroy the brain parenchyma (Kaye and Jr., 2001a). It 
comprises of glioma grade I, grade II, grade III and grade IV including pilocytic 
astrocytoma (WHO grade I), Oligodendroglioma (WHO grade II), Anaplastic 
astrocytoma (WHO grade III) and Glioblastoma Multiforme (WHO grade IV). 
 
1.2.2.1.1 ASTROCYTIC (GLIAL) TUMORS 
 
Three main categories of astrocytic brain tumors are astrocytoma, anaplastic 
astrocytoma and glioblastoma multiform (Doolittle, 2004). Other sub groups which 
are also categorized as astrocytic tumors are diffuse astrocytoma, anaplastic 
astrocytoma, glioblastoma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma 
and subependymal giant cell astrocytoma. They are differentially categorizied 
according to their clinical, histopatological, and genetic features (Kleihues et al., 
2002).  
 
Among the three major categories of astrocytic tumors, anaplastic astrocytoma and 
glioblastoma multiform are the most common glial tumors. Anaplastic astrocytoma is 
graded as tumor grade 3 and glioblastoma multiform is graded as tumor grade 4 
(Doolittle, 2004, Kaye and Jr., 2001b). Among all types of astrocytic tumors, 
glioblastoma is the most frequent brain tumor occurs in adults (Kaye and Jr., 2001b, 
RobertWechsler-Reya and Scott, 2001). Astrocytoma may be detected superficially 
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in the cerebral hemispheres, and may involve overlying meninges (Kaye and Jr., 
2001b).  
 
1.2.2.1.2 OLIGODENDROGLIAL TUMORS 
 
Basically, oligodendroglial tumors can be divided into two main groups, which are 
oligodendroglioma and anaplastic oligodendroglioma (Kaye and Jr., 2001b). 
Oligodendrogliomas constitute about 5 to 10% of the primary CNS glial neoplasms 
which usually occur in the cerebral hemispheres and consist of oligodendroglial cells 
(Kaye and Jr., 2001b). Most are identified in adults in their fourth and fifth decades of 
life, but oligodendrogliomas can occur at any age.   
 
1.2.2.1.3 EPENDYMAL TUMORS 
 
Ependymoma occurs most commonly in fourth ventricle, and in that location, it may 
cause hydrocephalus. Besides that, ependymoma has also been found in spinal 
cord, filum terminale and infrequently in the third ventricle. Ependymal tumors can be 
classified into four categories which are ependymoma, anaplastic (malignant) 
ependymoma, myxopapillary ependymoma, and subependymoma (Kaye and Jr., 
2001b). Previous documented cases of ependymal tumors showed no partiality of 
age or sex in the CNS (Kleihues et al., 2002).   
 
1.2.2.2 MEDULLOBLASTOMA 
 
Medulloblastomas, are the most common primary brain tumors among children 
(Fomchenko and Holland, 2005). Normally, medulloblastomas arise in the 
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cerebellum and it occurs more frequently in males compared to females. There are a 
few genes which are closely correlated to the development of medulloblastomas, 
such as LOH on chromosome 17q, EGFR, HER2, HER3, HER4, and cyclin D2 
genes. 
 
1.2.2.3 MENINGIOMAS 
 
Meningiomas arise from the meningiothelial cells at meninges, which is the outer 
layer of the brain including parasagittal/falcine, convexity, sphenoid ridge, 
suprasellar, posterior fossa, olfactory groove, middle fossa, tentorial and peritorcular 
(Kaye and Jr., 2001b). It may occur as benign, atypical or malignant tumors. 
Basically, meningiomas are slow-growing and are not associated with edema: 
however, they cause symptoms by compressing adjacent neural structures. 
Meningiomas encompass almost 20% of the central nervous system tumors 
(Doolittle, 2004) and they can be divided into four major sub-groups, which are tumor 
of meningiothelial cells, mesenchymal, non-meningiothelial tumors, primary 
melanocytic lesions, and tumors of uncertain origin (Kaye and Jr., 2001b). 
Meningiomas usually occur higher in patients older than 70 years old in both sexes. 
Only 1-2% of meningiomas are detected in children, suggesting that meningiomas 
are rarely found in children (Kaye and Jr., 2001b). 
 
1.2.2.4 Other types of CNS tumors 
 
Other types of CNS tumors include Germ Cell Tumors and Tumors of the Sellar 
Region which are included in the Table 1.1. 
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According to the National Cancer Registry, Malaysia (Chye and Yahaya, 2003), brain 
tumors are the second most frequent reported cases after leukemia in Malaysia. The 
tumors are more frequently reported in male as compared to women. Brain tumor 
patients of age between 30-39 years old (Mouriaux et al.) seems to render the highest 
percentage with 17.3%, while patients of age 30-39 and 50-59 years old (female) are the 
second and third most reported cases with 16.4% respectively. Brain tumors are 
reported most among Indian male patients with 31.4% and Chinese female patients with 
27.5% (Chye and Yahaya, 2003).  
 
Among all types of brain tumors, glioma is the most common type found in adults (Park 
et al., 2004, Tyynela, 2006). Malignant gliomas have been treated with the standard 
treatment of tumor resection followed by radiation therapy with or without adjuvant 
chemotherapy. Even though advances in neurosurgical techniques, radiation therapy 
and drug deliveries have emerged, the prognosis of the patients remain poor (Lam and 
Breakefield, 2001, Tyynela, 2006). Besides gliomas, meningiomas are also categorized 
as one of the most reported central nervous tumor, accounting for 26% of primary brain 
tumors (Watson et al., 2002). Majority of meningioma cases also shows aggressive 
tumors features and caused mortality of the patients (Mihaila et al., 2003). Treatments 
for meningiomas are usually limited to surgical intervention and radiation (Watson et al., 
2002). Molecular genetics and histopatological studies on meningiomas are very limited 
so far, as compared to other malignant brain tumors such as gliomas. In this study, we 
are focusing on both meningiomas and gliomas for the molecular genetics and 
histopatological studies to understand the role of cell cycle genes and their protein in 
brain tumor development and to gain valuable information which might further help in 
developing new treatments modalities for meningiomas and gliomas.   
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1.3 CELL CYCLE 
 
Cell division cycle serves as the important mechanism which allows cell grows and 
duplicates by replicating its DNA and then divides to form two daughter cells. Cell cycle 
process comprises of four distinct chronological phases, which are G1, S, G2 and M 
phases (Figure 1.1) (Garrett, 2001). The sequence begins with a silent gap period, G1, 
followed by a period during which new DNA is synthesized in a semi conserved fashion, 
called the S phase or period. Following that is another gap period, G2, then the M 
phase, during which the actual cell division/mitosis takes place.   
 
The activities of cell cycle depend mostly on the sequential series of checkpoints which 
lie amongst the four significant phases, ensuring that the conditions are suitable for the 
proper function of that cell and for DNA replication and cytokinesis (Humphrey and 
Brooks, 2005). Each check point is made up of sensor mechanism that detects aberrant 
or incomplete cell cycle events such as DNA damage, signal transduction pathway 
which carries the signal from the sensor to the third component and the effectors that 
can invoke a cell cycle arrest until the problem has been resolute. The first checkpoint 
occurs at G1/S phase transition and is the major sensor of DNA damage. Other 
checkpoints involve in cell cycle  are G2/M phase transition and spindle checkpoint, 
which may arrest the cell cycle progression due to DNA damage and incomplete 
formation of functional mitotic spindle, respectively (Garrett, 2001). The mechanisms 
involved in cell division must be precise. Any error, whether in the replication of DNA or 
the distribution of the genetic complement to the daughter cells, would have severe 
impact to the organism. Disruption of cell cycle checkpoints may lead to cellular 
proliferation, increase genomic instability and ultimately cancer development (Cheung et 
al., 2001, Garrett, 2001). 
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Figure 1.1: Checkpoints and cell cycle. 
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The cell cycle progression is tightly controlled by three families of key cell cycle 
regulatory proteins: cyclins and their catalytic subunits known as cyclin-dependent 
kinase (CDK), and cyclin-dependent kinase inhibitor (CDKI), (Cheung et al., 2001, 
Humphrey and Brooks, 2005) which themselves are regulated by phosphorylation and 
dephosphorylation events (Cheung et al., 2001, Humphrey and Brooks, 2005). Various 
CDKs, cyclins and CDKIs are involved in regulating cell cycle progression and different 
types of components control different stages of the cycle.  
 
Cyclin Dependent Kinases (CDKs) are the engines driving the proliferative cycle, 
phosphorylating substrate to promote progression through cell cycle transitions, 
maintaining checkpoints functions and ensuring overall integrity of the process (Nho and 
Sheaff, 2003). The CDKs are activated once they are forming complexes with a cyclin 
regulatory subunit (Garrett, 2001).  In mammalian cells, different CDKs are active and 
required at different phases of the cell cycle. The cyclin levels vary dramatically through 
the cell cycle as a consequence of changes in transcription and ubiquitin-mediated 
degradation. Whilst the expression level of the CDKs subunit is generally constant 
throughout the cell cycle, the expression of each cyclin (of which there is a whole family) 
tends to be cell cycle dependent so that a specific CDKs will have full activity when its 
cyclin partner is expressed. The cyclins and CDKs activities are negatively regulated by 
association with various CDKIs (Garrett, 2001, Spirin et al., 1996).  
 
Briefly, five major classes of mammalian cyclins (termed as A-E) have been described. 
All the five major classes of cyclins are playing important roles in various stages of cell 
cycle. For example, cyclin C, D1-3, and E reach their peak of synthesis and activity 
during the G1 phase and apparently regulate the transition from G1 to S phase. On the 
other hand, cyclins A and B1-2 achieve their maximal level later in the cycle, during S 
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and G2 phases, and are regarded as regulators of the transition to mitosis. It is 
postulated that the G1/S transition is regulated by complexes of cyclin E/CDK2 and 
cyclin D/CDK4 or CDK6, while cyclin E-CDK2 controls entry into S phase. Cyclin A-
CDK2 units effect their regulation through S phase and cyclin B-CDC2 (also known as 
CDK1) control entry into mitosis. The kinase activity of these CDKs requires association 
between a catalytic subunit (the CDK) and a regulatory subunit (the cyclin) (Cordon, 
1995).  
 
In an active cell cycle processes, each cyclin binds to the corresponding CDK and 
activates its catalytic subunit. Activated CDK then phosphorylates another important of 
cell cycle regulator of G1 progression, the retinoblastoma protein, pRb which has 16 
potential sites of CDK phosphorylation. Once the pRb becomes phosphorylated at the 
CDK consensus sites, this will disrupt the interaction between pRb proteins with the E2F 
proteins, allowing the E2F dependent transcription to occur. This is required in order for 
the cell to pass through the restriction site late in G1. During G1 phase, Cyclin D1 is 
expressed throughout G1 phase but its peak occurs during mid G1. The main function of 
cyclin D1 is to activate CDK4/6 catalytic subunits to induce initial phosphorylation of 
pRb. Cyclins E and A begin to rise later in G1. They are responsible for activation of 
CDK2 to maintain pRb in its hyperphosphorylated state during the late G1 and ensure 
G1 to S progression. Figure 1.2 shows a schematic diagram of the temporal relationship 
between different cyclin/CDK complexes and cell cycle phases. Figure 1.3 shows the 
schematic representation of pRb phosphorylation by cyclin/CDK complexes and E2F 
release during G1 to S progression. 
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Figure 1.2: A schematic diagram showing the temporal relationship between different 
cyclin/CDK complexes and cell cycle phases. 
 
R – Late G1 restriction site 
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Figure 1.3: Schematic representation of pRb phosphorylation by cyclin/CDK complexes 
and E2F release during G1 to S progression. 
 
 
 
 
 
 
 
 
As cells progress into S phase, cyclin A is expressed and becomes the primary cyclin 
associated with CDK2. This switching of cyclin partner allows CDK2 to also switch 
substrate specificity so that it can now target to a new set of proteins during S phase, 
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including CDC6 and E2F. CDC6 is a protein required for initiation of replication which 
when phosphorylated by CDK2/cyclin A, will relocalize from the nucleus to the 
cytoplasm. Progression from G2 into mitosis requires the activity of the CDK, CDC2 
(also known as CDK1) complexed with cyclin B, which has been shown to phosphorylate 
proteins regulated during mitosis. Figure 1.4 shows the cyclins and CDKs which are 
required in cell cycle. 
 
Interestingly, the kinase activity of CDKs can be inhibited by various kinase inhibitors 
(Fredersdorf et al., 1997). There are two classes of CDKIs which are negatively 
regulating the CDK activities. They are categorized based on their structural and 
functional homologies. One class is known as INK4-proteins which includes p16/INK4A, 
p15/INK4B, p18/INK4C and p19/INK4D. The other group is so-called CIP/KIP group, 
which includes p21/WAF1, p21/Kip1 and p57/Kip2 (Spirin et al., 1996).  
 
Cyclin-dependent kinase inhibitors (CDKIs) are generally regulating Cyclin-CDK 
complexes during cell cycle progression. These proteins (CDKIs) are grouped into two 
families based on their structural functional properties. The INK4 group has four anykrin 
repeats and form complexes with CDK4 and/or CDK6 and the D-type cyclins. They have 
functional activities that are dependent on the presence of a normal retinoblastoma 
protein (Lloyd et al., 1999). Maximal expression of the INK4 proteins occurs during the 
middle of the S phase in proliferating cells. Among all types, both p15 and p16 show a 
high frequency of gene deletions in various human cancer types, suggesting that these 
genes may function as tumor suppressors. 
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Figure 1.4: Cyclins, CDKs and the cell cycle. 
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The second family of inhibitors is composed of Cip/Kip family, includes p21/WAFI/CIP1 
(p21), p27/Kip1 (p27) and p57/Kip2 (p57). Proteins of this family act by inhibiting kinase 
activities of pre-activated G1 cyclin E-CDK2, cyclin D-CDK4/6, and other cyclins (Lloyd et 
al., 1999). These proteins are not specific for a particular phase (Coqueret, 2003) and 
they are designated as universal CDKIs because they interact with various CDK 
complexes, with cyclins A, E, D1, D2, and D3 and CDKs. Overexpression of the Kip 
proteins leads to cell cycle arrest. Members of the kip proteins share a great deal of 
homology. p27 protein has a 42% amino acid homology with p21 and a 47% homology 
with p57 at the amino-terminal domain, the region that mediates inhibition of CDK. Kip 
proteins all have a nuclear localization signal at their carboxyl-terminal domain. Unlike 
the INK4 family, which inhibits CDK4/6 only, the Cip/Kip inhibitors can also target CDK2 
in complexes (Lloyd et al., 1999).  
 
1.3.1 P27 GENE  
 
p27 (kip1/p27kip1) is one of the cyclin-dependent kinase inhibitors (CDKI), which also 
plays important roles as a negative regulator in cell cycles (Coqueret, 2003, Keles et al., 
2003). P27 is encoded by CDKN1B gene, which is located on chromosome 12q13 at the 
junction of 12p12-12p13.1. The gene consists of three exons and encoded for 4.99 kb of 
DNA. 
 
p27 is a CKI specific for CDK2 and normally acts at the G1 stage (Coqueret, 2003, 
Nakayama et al., 1996, Nho and Sheaff, 2003). p27 protein has separate binding sites 
for different cyclins and CDK subunits, explaining how this protein and other Kip/Cip 
inhibitors can bind isolated subunits.  
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p27 was first identified as a CKI due to its ability to block the activity of cyclin E/CDK2 
and cyclin A/CDK2 in cells arrested in G1 by TGF-ß, lovastatin and contact inhibition 
(Kudo et al., 2005). The association of p27 with CDK-4 cyclin D or with CDK2-cyclin E 
complexes blocks phosporylation of CDK4 on Thr 172 and CDK2 on Thr 160 via CDK 
activation kinases. p27 can be induced by cyclic AMP and other negative regulators of 
the cell cycle and can be down-regulated by interleukin 2 (Lloyd et al., 1999). 
 
p27 is generally viewed as an integral component of the cell cycle machinery controlling 
the cell's proliferative capacity. The levels of p27 protein increased in quiescent cells and 
rapidly decreased after stimulation with mitogens or as cells reenter the cell cycle 
(Clurman and Porter, 1998, Lloyd et al., 1999). p27 can directly binds to the cyclin-CDK 
complexes and inhibit their enzymatic activities (Coqueret, 2003, Lloyd et al., 1999). This 
will disrupt the progression of G1 to S phase and leads to apoptosis of the cells (Kang et 
al., 2002). In addition to its role as a CDKI, p27 is a putative tumor suppressor gene, 
regulator of drug resistance in solid tumors, and a promoter of apoptosis (Lloyd et al., 
1999). 
 
There are two findings which contribute to the indication of p27 as a putative tumor 
suppressor gene. The first evidence showed that p27-knockout mice developed 
multiorgan hyperplasia and parathyroid tumor, and p27 haplo-insufficient mice have 
become more sensitive to tumor development induced by radiation or chemical 
carcinogens. Furthermore, adenoviral gene transfer of p27 into breast cancer cell lines 
has shown successful results in arresting the cell cycle progression and apoptosis. They 
have also demonstrated that the transduction of p27 via an adenoviral vector into human 
lung cancer cell lines induces cell growth suppression via G1-S arrest (Park et al., 2004).  
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1.3.1.1  Regulation of p27 expression 
  
In most of the cellular system, p27 levels are significantly regulated at the level of both 
protein translation and protein stability (Lloyd et al., 1999, Philipp-Staheli et al., 2001). In 
relation to that, it has been proposed that p27 half-life is much longer in quiescent cells 
compared to proliferating cells. There are three mechanisms by which the levels of p27 
are controlled, ie. ubiquitination/phosphorylation and methylation (Lloyd et al., 1999). 
 
Ubiquitination and/or proteosome activities are the believed procedures which control 
the p27 protein degradation (Figure 1.5) (Lloyd et al., 1999). Enhancement of the 
proteasomal degradation may result to the decrement of p27 levels (Nho and Sheaff, 
2003). Enzymes E1, E2 and E3 are 3 important enzymes which involve in the 
ubiquitination process, targeting on the ubiqutin-target protein complex specifically. 
These three enzymes are targeting on ubiquitin molecules, internal cystein residue and 
internal systemic residue which involve in ubiquitination processes. Another mechanism 
which has been shown to contribute in ubiquitination processes is phosphorylation 
(Lloyd et al., 1999). p27 phosphorylation is actively taking place during S and G2 phase 
in cell cycle progression (Lloyd et al., 1999, Sa and Stacey, 2004). Increasing evidences 
indicate that p27 must be initially phosphorylated by cyclin E/CDK2 on Thr187. The p27 
phosphorylation occurs on a conserved carboxyl-terminal CDK target site before being 
degraded by the proteasome (Lloyd et al., 1999, Nho and Sheaff, 2003, Sa and Stacey, 
2004).  
 
Another important mechanism which regulates the p27 levels in cells is DNA methylation 
(Lloyd et al., 1999, Nakatsuka et al., 2003). p27 methylation has been observed in the 
lymphoid malignancies suggesting that the mechanism might contribute to the loss of 
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p27 expression which give the cell proliferative advantage (Nakatsuka et al., 2003). 
However, the ultimate importance of methylation of p27 gene in regulating its function is 
not known (Lloyd et al., 1999).    
 
1.3.1.2 p27 and cancer 
  
Since the last few years, many researches have been carried out concerning the 
importance of p27 expression in many types of tumors. p27 has met the three criteria 
which validate it to be a prognostic marker and/or diagnostic marker. According to Steeg 
and Abrams (Steeg and Abram, 1997), as a new prognostic marker, it must provides 
information independent of and better than conventional pathological criteria, it should 
also gives information that can alter treatment decisions and the studies with the marker 
are reproducible (Lloyd et al., 1999).  
 
The level of p27 protein expression is the most crucial component which has been 
studied. In many of the reported studies, p27 protein expression often showed 
decrement in more aggressive tumors, such as brain tumors (Park et al., 2004), breast 
carcinoma, pituitary tumors, oral squamous cell carcinoma and lung non-small cell 
carcinoma (Kudo et al., 2005, Lloyd et al., 1999). In the studies done by Fuse at al. 
(Fuse et al., 2000) and Kirla et al. (Kirla et al., 2003) showed that decrement of p27 
protein expression occurred in higher grades of brain tumors. 
 
Downregulation of p27 protein expression is believed to contribute in cancer progression 
by upregulating cyclin-CDK activities, which drive inappropriate cell cycle progression 
and lead to uncontrolled proliferation of cancer cells (Nho and Sheaff, 2003). 
 
